{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:48:05Z","timestamp":1788220085226,"version":"build-2803163510"},"reference-count":21,"publisher":"FapUNIFESP (SciELO)","issue":"7","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY  BACKGROUND: Rheumatoid arthritis is a chronic inflammatory disease that often necessitates combination therapy. The presence of comorbidities, frequently observed in rheumatoid arthritis patients, can further increase the number of medications required, raising the risk of drug-to-drug interactions.  OBJECTIVE: This study aimed to analyze the prevalence of polypharmacy and identify potential drug-to-drug interactions in rheumatoid arthritis patients using the MedScape\u00ae digital platform.  METHODS: A retrospective analysis was conducted on 370 rheumatoid arthritis patients. Data on epidemiological characteristics, comorbidities, and the number of medications used during treatment were collected. The MedScape\u00ae platform was employed to assess potential drug-to-drug interactions.  RESULTS: Polypharmacy was observed in 81.1% of the patients, with a higher prevalence among older individuals and those with multiple comorbidities. The MedScape\u00ae platform identified 2,018 potential drug-to-drug interactions in the sample, of which 27.5% were mild, 54.4% moderate, and 17.8% severe. Severe interactions frequently involved combinations of antirheumatic drugs.  CONCLUSIONS: Polypharmacy is highly prevalent in rheumatoid arthritis treatment, particularly in patients with comorbidities, increasing the risk of clinically significant drug-to-drug interactions. Physicians should remain vigilant in monitoring for potential interactions and adopt strategies to mitigate the risks, such as regular medication reviews and utilizing digital platforms to support clinical decision-making. This approach is critical to optimizing patient safety and treatment outcomes in rheumatoid arthritis care.<\/jats:p>","DOI":"10.1590\/1806-9282.20250151","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T13:23:07Z","timestamp":1754659387000},"source":"Crossref","is-referenced-by-count":4,"title":["Polypharmacy and drug interactions in the management of rheumatoid arthritis"],"prefix":"10.1590","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4319-222X","authenticated-orcid":false,"given":"Lorena Batista","family":"Boeing","sequence":"first","affiliation":[{"name":"Mackenzie Evangelical School of Medicine,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-3718","authenticated-orcid":false,"given":"Natalie Sbalqueiro","family":"Foga\u00e7a","sequence":"additional","affiliation":[{"name":"Mackenzie Evangelical School of Medicine,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-2777","authenticated-orcid":false,"given":"Barbara Stadler","family":"Kahlow","sequence":"additional","affiliation":[{"name":"Mackenzie Evangelical School of Medicine,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-3542","authenticated-orcid":false,"given":"Thelma","family":"Skare","sequence":"additional","affiliation":[{"name":"Mackenzie Evangelical School of Medicine,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-8093","authenticated-orcid":false,"given":"Renato","family":"Nisihara","sequence":"additional","affiliation":[{"name":"Mackenzie Evangelical School of Medicine,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2025]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon N","year":"2017","journal-title":"BMC Geriatr"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.16418","article-title":"The effect of polypharmacy on rheumatoid and psoriatic arthritis treatment: retrospective study","volume":"11","author":"Kara M","year":"2023","journal-title":"PeerJ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"9s","DOI":"10.1590\/s1518-8787.2016050006145","article-title":"Polypharmacy and polymorbidity in older adults in Brazil: a public health challenge","volume":"50","author":"Ramos LR","year":"2016","journal-title":"Rev Saude Publica"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.mayocp.2020.06.012","article-title":"Polypharmacy management in older patients","volume":"96","author":"Hoel RW","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref6","article-title":"Metabolic consequences of rheumatoid arthritis","author":"Barry S","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3899\/jrheum.160818","article-title":"Polypharmacy and unplanned hospitalizations in patients with rheumatoid arthritis","volume":"44","author":"Filkova M","year":"2017","journal-title":"J Rheumatol"},{"issue":"9","key":"ref8","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha D","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6","key":"ref9","first-page":"11","article-title":"Six mobile apps to make prescribing easier","volume":"25","author":"Rebedew D","year":"2018","journal-title":"Fam Pract Manag"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.reuma.2024.02.006","article-title":"Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease","volume":"20","author":"Lozano-Lozano R","year":"2024","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/2168479017725556","article-title":"Mobile health applications for caring of older people: review and comparison","volume":"52","author":"Anthony Berauk VL","year":"2018","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/2168479017725557","article-title":"Mobile health applications for pediatric care: review and comparison","volume":"52","author":"Morse SS","year":"2018","journal-title":"Ther Innov Regul Sci"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s11606-019-05230-0","article-title":"Comparative effectiveness of combining MTX with biologic drug therapy versus either MTX or biologics alone for early rheumatoid arthritis in adults: a systematic review and network meta-analysis","volume":"34","author":"Donahue KE","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"103530","DOI":"10.1016\/j.autrev.2024.103530","article-title":"Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: an analysis of current evidence","volume":"23","author":"Sun X","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15945","article-title":"Fatal low-dose methotrexate toxicity: a case report and literature review","volume":"35","author":"Ouellette S","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200427050-00006","article-title":"Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity","volume":"27","author":"Roon EN","year":"2004","journal-title":"Drug Saf"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis JR","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3899\/jrheum.201248","article-title":"Safety of the methotrexate-leflunomide combination in rheumatoid arthritis: results of a multicentric, registry-based, cohort study (BiobadaBrasil)","volume":"48","author":"Bredemeier M","year":"2021","journal-title":"J Rheumatol"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2665-9913(22)00028-5","article-title":"Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial","volume":"4","author":"Mulder MLM","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/ard-2024-226620","article-title":"Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial","volume":"84","author":"Ruyssen-Witrand A","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"37","key":"ref21","article-title":"The efficacy of statins in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"102","author":"Ren C","year":"2023","journal-title":"Medicine (Baltimore)"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0104-42302025000700622&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T13:23:10Z","timestamp":1754659390000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302025000700622&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025]]}},"alternative-id":["S0104-42302025000700622"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.20250151","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e20250151"}}